ascopubs.org3d
Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy.
Efficacy of 177Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis. Safety profile of lutetium-177 in patients with impaired renal function: A retrospective ...
ascopubs.org4d
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML ...
ascopubs.org5d
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...
ascopubs.org5d
Challenges in the Management of Advanced Prostate Cancer
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Fig 1. Challenges in the management of advanced prostate cancer.
ascopubs.org5d
Clinical outcomes of invasive primary urethral cancer: A real world multi-institutional study.
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell ...
ascopubs.org5d
Erratum: Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome
The article by Biller et al entitled “Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome” (JCO Precision Oncology 10.1200/PO-24 ...